Isgren C M, Edwards T, Pinchbeck G L, Winward E, Adams E R, Norton P, Timofte D, Maddox T W, Clegg P D, Williams N J
Institute of Infection and Global Health, University of Liverpool, Neston, England.
Research Centre for Drugs and Diagnostics, Liverpool School of Tropical Medicine, Liverpool, England.
BMC Vet Res. 2019 Jul 29;15(1):268. doi: 10.1186/s12917-019-2011-9.
This study investigated changes over time in the epidemiology of extended-spectrum β-lactamase (ESBL) producing Escherichia coli within a single equine referral hospital in the UK. Faecal samples were collected from hospitalised horses in 2008 and 2017, processed using selective media and standard susceptibility laboratory methods. A novel real-time PCR with high resolution melt analysis was used to distinguish bla and bla within CTX-M-1 group.
In 2008, 457 faecal samples from 103 horses were collected, with ESBL-producing E. coli identified in 131 samples (28.7, 95% CI 24.6-33.1). In 2017, 314 faecal samples were collected from 74 horses with ESBL-producing E. coli identified in 157 samples (50.0, 95% CI 44.5-55.5). There were 135 and 187 non-duplicate ESBL-producing isolates from 2008 and 2017, respectively. In 2008, 12.6% of isolates belonged to CTX-M-1 group, all carrying bla, whilst in 2017, 94.1% of isolates were CTX-M-1 group positive and of these 39.2 and 60.8% of isolates carried bla and bla, respectively. In addition, the prevalence of doxycycline, gentamicin and 3rd generation cephalosporin resistance increased significantly from 2008 to 2017 while a decreased prevalence of phenotypic resistance to potentiated sulphonamides was observed.
The real-time PCR proved a reliable and high throughput method to distinguish between bla and bla. Furthermore, its use in this study demonstrated the emergence of faecal carriage of CTX-M-15 in hospitalised horses, with an increase in prevalence of ESBL-producing E. coli as well as increased antimicrobial resistance to frequently used antimicrobials.
本研究调查了英国一家单一的马匹转诊医院内产超广谱β-内酰胺酶(ESBL)大肠杆菌的流行病学随时间的变化情况。2008年和2017年从住院马匹采集粪便样本,使用选择性培养基和标准药敏实验室方法进行处理。采用一种新型的高分辨率熔解分析实时PCR来区分CTX-M-1组内的bla和bla。
2008年,从103匹马中采集了457份粪便样本,131份样本(28.7%,95%可信区间24.6 - 33.1)中鉴定出产ESBL大肠杆菌。2017年,从74匹马中采集了314份粪便样本,157份样本(50.0%,95%可信区间44.5 - 55.5)中鉴定出产ESBL大肠杆菌。2008年和2017年分别有135株和187株非重复的产ESBL分离株。2008年,12.6%的分离株属于CTX-M-1组,均携带bla,而2017年,94.1%的分离株为CTX-M-1组阳性,其中39.2%和60.8%的分离株分别携带bla和bla。此外,从2008年到2017年,强力霉素、庆大霉素和第三代头孢菌素耐药率显著增加,而对增效磺胺类药物的表型耐药率则有所下降。
实时PCR被证明是一种可靠且高通量的方法,可区分bla和bla。此外,本研究中使用该方法证明了住院马匹粪便中CTX-M-15的携带情况出现,产ESBL大肠杆菌的患病率增加,以及对常用抗菌药物的耐药性增加。